Changes in design of Meril Life Sciences Myval Transcatheter Heart Valve approved by CDSCO panel
New Delhi: Approving the minor changes proposed by the Meril Life Sciences regarding the design of Myval Transcatheter Heart Valve (THV) and ballon catheter, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has asked Meril Life Sciences, an indigenous global medical devices company, to submit Post Marketing surveillance (PMS) data periodically to CDSCO for review.
Meril Life Sciences introduced the first ever indigenously designed and manufactured Transcatheter Aortic Heart Valve (TAVR) - Myval in 2018. The Myval TAVR technology had received approval for use by Central Drugs Standard Control Organization (CDSCO) on the basis of successful results from a clinical trial done in India.
With the launch, Meril, became the first Indian company to make Transcatheter Aortic Heart Valve Replacement (TAVR) Therapy commercially available on the world stage.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.